Mga Batayang Estadistika
| LEI | 549300UUNWK8TRT5EW12 |
| CIK | 1621227 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 29, 2025 |
Exhibit 10.2 SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August 29, 2025 by and between Adaptimmune, LLC (“Adaptimmune”) and John Lunger (“Lunger”) and is effective as of the Effective Date as defined in Section 9 below. WHEREAS, Lunger and Adaptimmune previously entered into an Employment Agreement, dated as of August 1, 2019 (the “Employment Agree |
|
| August 29, 2025 |
Exhibit 10.1 29 August 2025 Mr Gavin Wood [*] Dear Gavin I refer to the letter agreement dated 18 December 2024 as varied by a letter agreement dated 14 April 2025 in relation to the termination of your employment on 31 August 2025 (the “Termination Date”) by reason of redundancy (the “Letter Agreement”). The Remuneration Committee of the board of directors of Adaptimmune Therapeutics plc (the “Co |
|
| August 15, 2025 |
Exhibit 10.1 SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August 15, 2025 by and between Adaptimmune, LLC (“Adaptimmune”) and Cintia Piccina (“Piccina”) and is effective as of the Effective Date as defined in Section 9 below. WHEREAS, Piccina and Adaptimmune previously entered into an Employment Agreement, dated as of February 26, 2024 (the “Employme |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 13, 2025 |
Exhibit 99.1 Adaptimmune Reports Q2 Financial Results and Provides Business Update Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone payments Following the transaction, A |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAP |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 7, 2025 |
Separation Agreement dated as of August 7, 2025 by and between Adaptimmune, LLC and Elliot Norry. Exhibit 10.1 SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August 7, 2025 by and between Adaptimmune, LLC (“Adaptimmune”) and Elliot Norry (“Norry”) and is effective as of the Effective Date as defined in Section 9 below. WHEREAS, Norry and Adaptimmune previously entered into an Employment Agreement, dated as of December 16, 2020 (the “Employment Agre |
|
| August 7, 2025 |
Brewer Letter Agreement dated August 7, 2025 Exhibit 10.2 7 August 2025 Dr Joanna Brewer [*] Dear Jo I am writing to set out the arrangements which the Remuneration Committee of the board of directors of Adaptimmune Therapeutics plc (the “Company”) has agreed in relation to the termination of your employment by reason of redundancy. ● Your role as Chief Scientific Officer of the Company and your employment with Adaptimmune Limited will termi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| July 31, 2025 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On July 31, 2025, Adaptimmune Limited (“Seller”), a wholly-owned subsidiary of Adaptimmune Therapeutics plc (together with Seller, “Adaptimmune”), sold to USWM CT, LLC (“Purchaser”), a subsidiary of US WorldMeds Partners, LLC (together with Purchaser, “US WorldMeds”) the assets and rights related to Adaptimmune’s TECELRA, |
|
| July 28, 2025 |
Exhibit 99.1 Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummatio |
|
| July 28, 2025 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT between ADAPTIMMUNE LIMITED, USWM CT, LLC and US WORLDMEDS PARTNERS, LLC (solely for the purposes of Section 10.14) DATED AS OF JULY 27, 2025 1 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND TERMS 1 Section 1.01. Definitions 1 Section 1.02. Other Definitional Provisions 19 ARTICLE II PURCHASE AND SALE 20 Section 2.01. Purchase and Sale of Assets 20 Section 2. |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADA |
|
| May 13, 2025 |
Exhibit 99.1 Adaptimmune Reports Q1 Financial Results and Provides Business Update TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 1, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 18, 2025 |
As filed with the Securities and Exchange Commission on April 18, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 18, 2025 Registration No. |
|
| April 18, 2025 |
Exhibit 1.3 Execution Version ADAPTIMMUNE THERAPEUTICS PLC $200,000,000 AMERICAN DEPOSITARY SHARES each representing 6 Ordinary Shares AMENDMENT NO. 1 TO SALES AGREEMENT April 18, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York 10017 Ladies and Gentlemen: Adaptimmune Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), together with |
|
| April 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adaptimmune Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value £0. |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| April 14, 2025 |
Variation Letter Agreement dated April 14, 2025 Exhibit 10.1 14 April 2025 Mr Gavin Wood [*] Dear Gavin I refer to the letter agreement dated 18 December 2024 in relation to the termination of your employment on 31 May 2025 (the “Termination Date”) by reason of redundancy (the “Letter Agreement”). The Remuneration Committee of the board of directors of Adaptimmune Therapeutics plc (the “Company”) has agreed to vary the Letter Agreement as follo |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMM |
|
| March 24, 2025 |
Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Formation Adaptimmune Limited England and Wales Adaptimmune LLC Delaware Adaptimmune B.V. The Netherlands CM Intermediate Sub I, Inc. Delaware CM Intermediate Sub II, Inc. Delaware TCR² Therapeutics Inc. Delaware TRUCS Therapeutics Limited England and Wales |
|
| March 24, 2025 |
Exhibit 10.46 Execution Version FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 24, 2025, is entered into by and among ADAPTIMMUNE THERAPEUTICS PLC, a public limited company registered under the laws of England and Wales with company number 09338148 (“Parent” and “Company”), ADAPTIMMUNE LLC, a Delaware limited liab |
|
| March 20, 2025 |
Exhibit 99.1 Adaptimmune Provides Q4 and Full Year 2024 Business Update TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduc |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| February 14, 2025 |
EX-99.1 2 exhibit99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the Ordinary Shares, par value £0.001 per share, of Adaptimmune Therapeutics plc. |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| December 19, 2024 |
Exhibit 99.1 Adaptimmune Announces Changes to its Executive Leadership Team Based in the UK Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 PHILADELPHIA & OXFORD, England, December 19, 2024-Adaptimmune Therapeutics plc (NA |
|
| December 19, 2024 |
Dr. Helen Tayton-Martin Letter Agreement dated December 18, 2024 Exhibit 10.1 18 December 2024 Dr Helen Tayton-Martin [*] Dear Helen I am writing to set out the arrangements which the Remuneration Committee of the board of directors of Adaptimmune Therapeutics plc (the “Company”) has agreed in relation to the termination of your employment by reason of redundancy. ● Your role as Chief Business & Strategy Officer of the Company and your employment with Adaptimmu |
|
| December 19, 2024 |
Gavin Wood Letter Agreement dated December 18, 2024 Exhibit 10.2 18 December 2024 Mr Gavin Wood [*] Dear Gavin I am writing to set out the arrangements which the Remuneration Committee of the board of directors of Adaptimmune Therapeutics plc (the “Company”) has agreed in relation to the termination of your employment by reason of redundancy. ● Your role as Chief Financial Officer of the Company and your employment with Adaptimmune Limited will ter |
|
| November 13, 2024 |
Exhibit 99.1 Adaptimmune Reports Q3 2024 Financial and Business Updates Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall resp |
|
| November 13, 2024 |
Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 |
|
| November 13, 2024 |
Exhibit 10.1 (***) CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10). SUCH EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MUTUAL RELEASE AND RESOLUTION AGREEMENT This Settlement Agreement (the “Agreement”) is made and entered into as of September 23, 2024 (the “Effective Date”) |
|
| November 13, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Adaptimmune Therapeutics PLC (Name of Issuer) Ordinary Shares, par value £0.001 (Title of Class of Securities) 00653A107** (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| November 1, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| September 23, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpo |
|
| August 12, 2024 |
Exhibit 10.2 Collaboration and Exclusive License Agreement FINAL (***) CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT between ADAPTIMMUNE Limited and GALAPAGOS NV Dated as of 30 |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAP |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 12, 2024 |
Exhibit 10.1 (***) cERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10). SUCH excluded INFORMATION IS BOTH (I) NOT MATERIAL AND (II) the type that the registrant treats as private or confidential. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 14, 2024 and is entered into by and among ADAPTIMMUNE THERAPEUTICS P |
|
| August 12, 2024 |
Exhibit 99.1 Adaptimmune Reports Q2 2024 Financial and Business Updates Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity1 of $214.8 million PHILADELPHI |
|
| August 2, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| August 2, 2024 |
Exhibit 99.1 Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold w |
|
| July 16, 2024 |
Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE SEVERANCE POLICY This Executive Severance Policy (“Policy”) has been established by Adaptimmune Therapeutics plc (the “Company”) on March 10, 2017, as amended and restated effective from June 11, 2024 and then on July 16, 2024 to provide Executives with the opportunity to receive severance benefits following termination of employment under certain condit |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| June 11, 2024 |
Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE SEVERANCE POLICY This Executive Severance Policy (“Policy”) has been established by Adaptimmune Therapeutics plc (the “Company”) on March 10, 2017 and amended and restated effective from June 11, 2024 to provide Executives with the opportunity to receive severance benefits following termination of employment under certain conditions. The purpose of the P |
|
| May 30, 2024 |
Exhibit 99.1 Adaptimmune and Galapagos sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications ● Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) pr |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 15, 2024 |
Exhibit 99.1 Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval PHILADELPHIA, PA. and OXFORD, UK, May 15, 2024 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell the |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADA |
|
| May 15, 2024 |
Exhibit 99.1 Adaptimmune Reports Q1 2024 Financial and Business Updates Afami-cel commercial and regulatory update presented at Company’s Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel pu |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| April 12, 2024 |
Exhibit 99.1 Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18th Investor Day PHILADELPHIA, P |
|
| April 11, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 2, 2024 |
SC 13D/A 1 nea14-adaptimmune18818.htm NEW ENTERPRISE ASSOCIATES 14, L.P. - ADAPTIMMUNE 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adaptimmune Therapeutics Plc (Name of Issuer) Ordinary Shares, £.001 par value per share (Title of Class of Securities) 00653A107 (CUSIP Number) Stephanie Br |
|
| April 1, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Adaptimmune Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.001 per share (Title of Class of Securities) 00653A107 (CUSIP Number) March 8, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| March 6, 2024 |
Exhibit 99.1 Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targetin |
|
| March 6, 2024 |
Exhibit 19.1 ADAPTIMMUNE THERAPEUTICS PLC INSIDER TRADING POLICY (Adopted by the Board of Directors of Adaptimmune Therapeutics plc on 11 January 2018, as amended on 2 March 2024) This Insider Trading Policy (“Policy”) applies to (a) the purchase or sale of securities, (including without limitation, the purchase or sale of puts, calls and options and acquisitions and dispositions of shares and gif |
|
| March 6, 2024 |
Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Formation Adaptimmune Limited England and Wales Adaptimmune LLC Delaware Adaptimmune B.V. The Netherlands CM Intermediate Sub I, Inc. Delaware CM Intermediate Sub II, Inc. Delaware TCR² Therapeutics Inc. Delaware TRUCS Therapeutics Limited England and Wales TRUC Securities Corporation Massachusetts |
|
| March 6, 2024 |
Description of the Registrant’s Securities. Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Adaptimmune Therapeutics plc (the “Company”, “we” or “us” and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMM |
|
| March 6, 2024 |
Exhibit 97.1 Adaptimmune Therapeutics plc POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Adaptimmune Therapeutics plc (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), by a resolution of the Board of Directors of the Company (the “Board”) on September 21, 2023, effective as of October 2, 2023 being the date when Listing Rule 5608 of t |
|
| February 27, 2024 |
Exhibit 99.1 Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise - Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 PHILADELPHIA and OXFORD, UK, February 27, 2024 – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell |
|
| February 27, 2024 |
Employment Agreement dated February 26, 2024 by and between Adaptimmune, LLC and Cintia Piccina Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made as of February 26, 2024 by and between Adaptimmune, LLC (the “Company”), a limited liability corporation and wholly-owned subsidiary of Adaptimmune Limited, and Cintia Piccina, an individual residing at [*****] (“Executive”). WHEREAS the Company and Executive desire to enter into this Agreement to establish and |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| February 16, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| February 14, 2024 |
SC 13G/A 1 adaptimmune13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADAPTIMMUNE THERAPEUTICS PLC (Name of Issuer) American Depositary Shares (Title of Class of Securities) 00653A107 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan |
|
| February 14, 2024 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the |
|
| February 14, 2024 |
SC 13G/A 1 tm242424d28sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adaptimmune Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.001 per share (Title of Class of Securities) 00653A107** (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Ch |
|
| January 31, 2024 |
Exhibit 99.1 Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review ● If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade PHILADELPHIA and OXFORD, UK, January, 31, 2024 – Adaptimmune |
|
| January 31, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| January 30, 2024 |
SC 13G 1 adaptimmune13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Adaptimmune Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.001 per share (Title of Class of Securities) 00653A107 (CUSIP Number) January 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| January 4, 2024 |
Exhibit 99.1 Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company prepari |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| December 6, 2023 |
Exhibit 99.1 Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial |
|
| November 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, £0. |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| November 8, 2023 |
Exhibit 99.1 Adaptimmune Reports Third Quarter Financial Results and Business Update Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this year SURPASS Phase 1 trial: 75% response rate in ovarian, urothelial, and head & neck cancers in patients with ≤ 3 prior lines of therapy |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADAPTIMMUNE THERAPEUTICS PLC (Name of Issuer) American Depositary Shares (Title of Class of Securities) 00653A107 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan, PR 00912 (787) 333-0240 (Name, Address a |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| November 8, 2023 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| October 31, 2023 |
Exhibit 99.1 Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS 40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review2; primary efficacy endpoint requires 16/60 patients have responses Median dur |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdict |
|
| August 10, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99. 3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X as amended by the final rule, Release No. 33 10786 “Amendments to Financial Disclosures about Acquired and Disposed Business” as adopted by the SEC on May 20, 2020. The un |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAP |
|
| August 9, 2023 |
Exhibit 99.1 Adaptimmune Reports Second Quarter Financial Results and Business Update Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay – submission now targeted for Q4 2023 Transition of lete-cel from GSK and data from the completed pivotal trial in synovial sarcoma and MRCLS expected in la |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| July 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Adaptimmune Therapeutics PLC (Name of Issuer) Ordinary Shares, par value £0.001 (Title of Class of Securities) 00653A107** (CUSIP Number) June 30, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 29, 2023 As filed with the Securities and Exchange Commission on June 29, 2023 Registration Nos. |
|
| June 29, 2023 |
Exhibit 10.2 RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2016 EMPLOYEE SHARE OPTION SCHEME Adopted by the Company on 14 January 2016 and amended on 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 12 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 14 7. EXERCISE and Lapse OF OPTIONS 15 8. M |
|
| June 29, 2023 |
Exhibit 10.1 RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2015 SHARE OPTION SCHEME Adopted by the Company on 16 March 2015 Amended on 15 April 2015, 13 January 2016, 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 11 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 15 7. EXERCISE and Lapse O |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 29, 2023 As filed with the Securities and Exchange Commission on June 29, 2023 Registration Nos. |
|
| June 1, 2023 |
Separation Agreement, dated June 1, 2023, by and between TCR2 and Garry E Menzel, PhD. Exhibit 10.1 CONFIDENTIAL June 1, 2023 Garry E Menzel, Ph.D By e-mail to: [email protected] Re: Separation Agreement Dear Garry On March 6, 2023, TCR2 Therapeutics Inc. (the “Company”, “we” or “TCR2) announced entry into a definitive agreement under which we will combine with Adaptimmune Plc in an all-stock transaction (the “Transaction”). By a letter dated June 1, 2023 you have resigned your positio |
|
| June 1, 2023 |
Exhibit 99.1 Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 |
|
| June 1, 2023 |
Exhibit 10.3 1 June 2023 Dr Priti Hegde [*] Dear Priti Letter of appointment The board of directors (“Board”) of Adaptimmune Therapeutics plc (“Company”) is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Corporate Governance and Nominating Committee with effect from 1 June 2023. The terms of this letter will apply with effect from |
|
| June 1, 2023 |
Exhibit 10.4 1 June 2023 Dr Garry Menzel [*] Dear Garry Letter of appointment The board of directors (“Board”) of Adaptimmune Therapeutics plc (“Company”) is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Audit Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be bas |
|
| June 1, 2023 |
Exhibit 10.2 1 June 2023 Andrew Allen, MD, PhD [*] Dear Andrew Letter of appointment The board of directors (“Board”) of Adaptimmune Therapeutics plc (“Company”) is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. Y |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 30, 2023 |
Filed by Adaptimmune Therapeutics plc Filed by Adaptimmune Therapeutics plc pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: TCR2 Therapeutics Inc. |
|
| May 22, 2023 |
425 1 tm2316416d2425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADA |
|
| May 12, 2023 |
Exhibit 99.1 Adaptimmune Reports First Quarter Financial Results and Business Update Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs; Adaptimmune will receive ~$37 million in upfront and milestone pay |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| April 20, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-271145 MERGER PROPOSED — YOUR VOTE IS VERY IMPORTANT Adaptimmune Therapeutics PLC Registered office: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX, U.K. Incorporated in England & Wales with registered no. 09338148 April 20, 2023 Dear Adaptimmune Therapeutics plc Shareholder: This letter, the notice of the gen |
|
| April 18, 2023 |
Consent of Piper Sandler & Co. Exhibit 99.2 CONSENT OF PIPER SANDLER & CO. Adaptimmune Therapeutics plc 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom The Board of Directors: We understand that Adaptimmune Therapeutics plc (the “Company”) has determined to include our opinion letter (the “Opinion”), dated March 5, 2023, to the Board of Directors of TCR2 Therapeutics Inc. (“TCR2”), as part of Amendm |
|
| April 18, 2023 |
Form of Proxy Card for Special Meeting of TCR Exhibit 99.4 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: P.O. BOX 8016, CARY, NC 27512-9903 TCR2 Therapeutics Inc. Special Meeting of Stockholders For Stockholders as of April 10, 2023 TIME: Tuesday, May 30, 2023 8:00 AM, Eastern Time PLACE: Special Meeting to be held live via the Internet - please visit www.proxydocs.com/TCRR for more details. This proxy is being solicited on behalf of the Board of D |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
CORRESP 1 filename1.htm April 18, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Adaptimmune Therapeutics plc Amendment No. 1 to Registration Statement on Form S-4 Filed April 18, 2023 Registration No. 333-271145 Ladies and Gentlemen: In accordance with |
|
| April 18, 2023 |
Form of Ordinary Shareholder Proxy Card for General Meeting of Adaptimmune Therapeutics plc. Exhibit 99.3 All Correspondence to: Computershare Investor Services PLC The Pavilions, Bridgwater Road, Bristol, BS99 6ZY Form of Proxy - General Meeting to be held on 30 May 2023 at 12.30 pm (London Time) To be effective, all proxy appointments must be lodged with the Company’s registrars at: Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY by 12.30 pm (London |
|
| April 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| April 11, 2023 |
Exhibit 10.1 certain identified information CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT because it is both not material and is the type that the registrant treats as private or confidential. TERMINATION AND TRANSFER AGREEMENT This TERMINATION AND TRANSFER AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 (the “Effective Date”), by and between Adap |
|
| April 11, 2023 |
Exhibit 99.1 Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune - Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO - -Adaptimmune will re |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 5, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 5, 2023 Registration No. |
|
| April 5, 2023 |
Consent of Cowen and Company, LLC. Exhibit 99.1 Consent of Cowen and Company, LLC The Board of Directors Adaptimmune Therapeutics plc 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated March 5, 2023, to the Board of Directors of Adaptimmune Therapeutics plc (“Adaptimmune”), as Annex D to, and reference to such opinion l |
|
| April 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Adaptimmune Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee (4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value £0. |
|
| April 5, 2023 |
Consent of Piper Sandler & Co. Exhibit 99.2 CONSENT OF PIPER SANDLER & CO. Adaptimmune Therapeutics plc 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom The Board of Directors: We understand that Adaptimmune Therapeutics plc (the “Company”) has determined to include our opinion letter (the “Opinion”), dated March 5, 2023, to the Board of Directors of TCR2 Therapeutics Inc. (“TCR2”), as part of the Co |
|
| April 5, 2023 |
EX-2.2 2 tm239007d3ex2-2.htm EXHIBIT 2.2 Exhibit 2.2 EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made and entered into as of April 5, 2023 by and among Adaptimmune Therapeutics plc (“Parent”), a public limited company incorporated in England and Wales, CM Merger Sub, Inc. (“Merger Sub”), a Delaware cor |
|
| April 3, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 30, 2023 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adaptimmune Therapeutics Plc (Name of Issuer) Ordinary Shares, £.001 par value per share (Title of Class of Securities) 00653A107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| March 9, 2023 |
Filed by Adaptimmune Therapeutics plc Filed by Adaptimmune Therapeutics plc pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: TCR2 Therapeutics Inc. |
|
| March 9, 2023 |
Filed by Adaptimmune Therapeutics plc Filed by Adaptimmune Therapeutics plc pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: TCR2 Therapeutics Inc. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 6, 2023 |
Exhibit 99.1 Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor 52% (13/25) response rate in ovarian, bladder and head & neck cancers in the Phase 1 SURPASS trial with next-generation MAGE- |
|
| March 6, 2023 |
COOKIE COMMS SCRIPT FOR WEBCAST Exhibit 99.3 COOKIE COMMS SCRIPT FOR WEBCAST Slide 1 – JPM · Thank you, operator · Hello - this morning we issued a joint press release with TCR2 Therapeutics - announcing entry into an agreement for the strategic combination of our two companies. Slide 2 - JPM · In a second press release - we provided our Q4 and full year 2022 financial and business updates · I would ask you to review the full te |
|
| March 6, 2023 |
C reating a preeminent cell therapy company Leading T he C ancer R evoluti on Exhibit 99.2 C reating a preeminent cell therapy company Leading T he C ancer R evoluti on 2 Disclaimer This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger, dated March 5 , 2023 , by and among Adaptimmune Therapeutics plc (“Parent”), CM Merger Sub, Inc . (“Merger Sub”), and TCR² Therapeutics Inc . (the “Company”) . This communication inc |
|
| March 6, 2023 |
EX-10.1 2 adap-20230302xex10d1.htm EX-10.1 Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT THIS SEPARATION AND CONSULTING AGREEMENT (together with Exhibit A, the “Agreement”) is made and entered into effective as of March 5, 2023 (“Effective Date”) by and between Adaptimmune, LLC (“Adaptimmune”) and Cintia Piccina (“Piccina”). WHEREAS, Piccina and Adaptimmune previously entered into an Employment |
|
| March 6, 2023 |
COOKIE COMMS SCRIPT FOR WEBCAST Exhibit 99.3 COOKIE COMMS SCRIPT FOR WEBCAST Slide 1 – JPM · Thank you, operator · Hello - this morning we issued a joint press release with TCR2 Therapeutics - announcing entry into an agreement for the strategic combination of our two companies. Slide 2 - JPM · In a second press release - we provided our Q4 and full year 2022 financial and business updates · I would ask you to review the full te |
|
| March 6, 2023 |
Exhibit 10.2 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 5, 2023 (the “Agreement Date”), by and among (a) Adaptimmune Therapeutics PLC (“Parent”), a public company limited by shares incorporated in England and Wales, (b) TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation and (c) [SHAREHOL |
|
| March 6, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AmONG Adaptimmune therapeutics plc, cm Merger sub, Inc. AND tcr2 therapeutics inc. Dated as of March 5, 2023 TABLE OF CONTENTS Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 Section 2 CONV |
|
| March 6, 2023 |
Exhibit 99.1 Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Follo |
|
| March 6, 2023 |
Exhibit 99.4 TO EMPLOYEES – March 6 Hi Everyone, We issued a press release this morning announcing our strategic combination with TCR2 to create a preeminent cell therapy company to treat solid tumors. We will hold a joint webcast for investors with Dr. Garry Menzel, TCR2’s CEO, at 8 a.m. EST / 1 p.m. GMT. We encourage you to join and it can be accessed HERE (with a replay available at that same a |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 6, 2023 |
Description of the Registrant’s Securities. Exhibit 4.4 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Adaptimmune Therapeutics plc (the “Company”, “we” or “us” and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” |
|
| March 6, 2023 |
C reating a preeminent cell therapy company Leading T he C ancer R evoluti on Exhibit 99.2 C reating a preeminent cell therapy company Leading T he C ancer R evoluti on 2 Disclaimer This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger, dated March 5 , 2023 , by and among Adaptimmune Therapeutics plc (“Parent”), CM Merger Sub, Inc . (“Merger Sub”), and TCR² Therapeutics Inc . (the “Company”) . This communication inc |
|
| March 6, 2023 |
Exhibit 99.4 TO EMPLOYEES – March 6 Hi Everyone, We issued a press release this morning announcing our strategic combination with TCR2 to create a preeminent cell therapy company to treat solid tumors. We will hold a joint webcast for investors with Dr. Garry Menzel, TCR2’s CEO, at 8 a.m. EST / 1 p.m. GMT. We encourage you to join and it can be accessed HERE (with a replay available at that same a |
|
| March 6, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AmONG Adaptimmune therapeutics plc, cm Merger sub, Inc. AND tcr2 therapeutics inc. Dated as of March 5, 2023 TABLE OF CONTENTS Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 Section 2 CONV |
|
| March 6, 2023 |
Exhibit 10.2 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 5, 2023 (the “Agreement Date”), by and among (a) Adaptimmune Therapeutics PLC (“Parent”), a public company limited by shares incorporated in England and Wales, (b) TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation and (c) [SHAREHOL |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMM |
|
| March 6, 2023 |
Exhibit 10.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 5, 2023 (the “Agreement Date”), by and among (a) Adaptimmune Therapeutics PLC (“Parent”), a public company limited by shares incorporated in England and Wales, (b) TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation and (c) [STOCKHOL |
|
| March 6, 2023 |
Exhibit 10.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of March 5, 2023 (the “Agreement Date”), by and among (a) Adaptimmune Therapeutics PLC (“Parent”), a public company limited by shares incorporated in England and Wales, (b) TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation and (c) [STOCKHOL |
|
| March 6, 2023 |
Exhibit 99.1 Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Follo |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporatio |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| February 16, 2023 |
15 February 2023 Kristen M. Hege, MD [*] Dear Kristen Letter of appointment The board of directors (“Board”) of Adaptimmune Therapeutics plc (“Company”) is pleased that you have agreed to join the Board as a non-executive director with effect from 1 November 2023. The terms of this letter will apply with effect from 1 November 2023. You will be based in, and perform your role as a non-executive, i |
|
| February 16, 2023 |
Adaptimmune Announces Changes to Board of Directors Adaptimmune Announces Changes to Board of Directors Philadelphia, Pennsylvania and Oxford, United Kingdom, February 16, 2023 - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced that Kristen M. |
|
| February 14, 2023 |
ADAP / Adaptimmune Therapeutics plc / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adaptimmune Therapeutics PLC (Name of Issuer) Ordinary shares, in the form of American Depositary Shares** (Title of Class of Securities) 00653 |
|
| February 13, 2023 |
ADAP / Adaptimmune Therapeutics plc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Adaptimmune Therapeutics PLC (Name of Issuer) Common Stock (Title of Class of Securities) G00818107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpor |
|
| December 20, 2022 |
Confidential FINAL Exhibit 10.1 ? certain identified information CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT because it is both not material and is the type that the registrant treats as private or confidential ? AMENDMENT AGREEMENT NO. 8 THIS AMENDMENT AGREEMENT is made and effective as of 19th December 2022 (the ?Amendment Effective Date?) ? BETWEEN ? 1. Adapt |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| November 8, 2022 |
Exhibit 99.1 Adaptimmune Reports Third-Quarter Financial Results and Business Update - Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors - - Adaptimmune will initiate a rolling BLA submission for afami-cel for the treatment of synovial sarcoma in Q4 2022 with target for completion in mid-year 2023 - -The Company will focus on advancin |
|
| November 8, 2022 |
Exhibit 99.1 Adaptimmune Reports Increased Response Rate and Durability of Response in its Phase 1 SURPASS trial; ORR now 52% across Ovarian, Urothelial, and Head & Neck Cancers - New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4CD8 - - Across the en |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| October 25, 2022 |
Exhibit 99.1 Adaptimmune Enhances its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK - Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 – - GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2023 - - A |
|
| September 9, 2022 |
Exhibit 99.1 ? ? Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors - 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers - - Further clinical development planned in ovarian (SURPASS-3), uroth |
|
| September 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 9, 2022 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or ot |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2022 |
Exhibit 99.1 ? Adaptimmune Reports Second-Quarter Financial Results and Business Update ? ? Reaffirming financial guidance; Company funded into early 2024 ? ? ? ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 ? ? ? Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress ? ? ? Quarterly call to be held today, August 4, 20 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 4, 2022 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or other |
|
| June 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 15, 2022 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or other |
|
| June 15, 2022 |
? ? ? Exhibit 10.2 ? ? ? ? ? ? ? DATED 15th June 2022 ? ? ? ? ? ? ? (1) MEPC MILTON PARK NO.1 LIMITED AND MEPC MILTON PARK NO.2 LIMITED ? ? ? and ? ? ? (2) ADAPTIMMUNE LIMITED ? ? ? ? deed of variation ? ? relating to a lease of ? ? 39 innovation drive Milton Park ? ? ? ? ? ? ? ? ? ? ? ? Knights plc Midland House West Way Botley Oxford OX2 0PH ? ? ? PARTICULARS 5 ? ? DATE : 15th June 2022 ? LANDLO |
|
| June 15, 2022 |
? ? ? ? Exhibit 10.1 ? ? ? ? ? ? ? DATED 15 June 2022 ? ? ? (1) MEPC MILTON PARK NO.1 LIMITED AND MEPC MILTON PARK NO.2 LIMITED ? ? ? and ? ? ? (2) ADAPTIMMUNE LIMITED ? ? ? ? ? ? deed of SURRENDER OF PART ? ? relating to a lease dated 28 February 2018 of ? 39 innovation drive Milton Park ? ? ? ? ? ? ? ? ? ? ? ? Knights plc Midland House West Way Botley Oxford OX2 0PH ? ? ? ? This Deed of Surrende |
|
| May 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 9, 2022 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or other ju |
|
| May 9, 2022 |
Exhibit 99.1 ? Adaptimmune Reports First Quarter Financial Results and Business Update ? - Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - ? - Preclinical data for two novel next-generation T-cell therapies to be presented in two posters at ASGCT - ? - Updated MAGE-A4 expression levels from the Com |
|
| May 9, 2022 |
ADAP / Adaptimmune Therapeutics plc / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Adaptimmune Therapeutics PLC (Name of Issuer) Ordinary shares, in the form of American Depositary Shares** (Title of Class of Securities) 00653A107 (CUSIP Number) April 28, 2022 (Date |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADA |
|
| May 9, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the ordinary shares of Adaptimmune Therapeutics, a public limited company incorporated under the laws of England and Wales, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Excha |
|
| May 4, 2022 |
? Exhibit 10.1 ? ? DATED 4th May 2022 ? (1) ADAPTIMMUNE LIMITED and (2) JOANNA BREWER ? EMPLOYMENT AGREEMENT ? ? ? ? ? Penningtons Manches LLP 9400 Garsington Road Oxford Business Park Oxford OX4 2HN ? Tel: +44 (0)1865 722106 Fax: +44 (0)1865 201012 ? ? ? ? ? ? Table of Contents 1. INTERPRETATION?3 2. APPOINTMENT?4 3. DURATION AND WARRANTIES?5 4. SCOPE OF THE EMPLOYMENT?5 5. HOURS AND PLACE OF WOR |
|
| May 4, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 4, 2022 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or other ju |
|
| May 4, 2022 |
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer Exhibit 99.1 Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer ? PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 4, 2022 - Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately. ? ?Jo Brewer is an exceptional scientific l |
|
| April 28, 2022 |
$200,000,000 American Depositary Shares representing Ordinary Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5)? ?Registration Statement No. 333-264208? PROSPECTUS SUPPLEMENT(To Prospectus dated April 22, 2022) ? $200,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated April 8, 2022, relating to the sale of our American Depositary Shares, or ADSs, offered by thi |
|
| April 21, 2022 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 21, 2022 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| April 21, 2022 |
As filed with the Securities and Exchange Commission on April 21, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 21, 2022 Registration No. |
|
| April 21, 2022 |
ADAPTIMMUNE THERAPEUTICS PLC 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom April 21, 2022 VIA EDGAR U. |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adaptimmune Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculationor Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value ?0. |
|
| April 8, 2022 |
EX-1.2 2 tm2212074d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 ADAPTIMMUNE THERAPEUTICS PLC $200,000,000 AMERICAN DEPOSITARY SHARES each representing 6 Ordinary Shares SALES AGREEMENT April 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Adaptimmune Therapeutics plc (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), |
|
| April 8, 2022 |
Power of Attorney (included in the signature page to this registration statement). TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 8, 2022 Registration No. |
|
| March 14, 2022 |
Description of the Registrant’s Securities. Exhibit 4.4 ? DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value ?0.001 per share, of Adaptimmune Therapeutics plc (the ?Company?, ?we? or ?us?) which are represented by American Depositary Shares (?ADSs?) with each ADS representing six of our ordinary shares registered |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| March 14, 2022 |
Exhibit 99.1 ? Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update ? - SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - ? - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022 - ? - Allogen |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Pe |
|
| January 26, 2022 |
Exhibit 10.01 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of January 26, 2022 by and between Adaptimmune, LLC (the ?Company?), a limited liability corporation and wholly-owned subsidiary of Adaptimmune Limited, and Cintia Piccina, an individual residing at [*****] (?Executive?). WHEREAS the Company and Executive desire to enter into this Agreement to establish and |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorpora |
|
| January 26, 2022 |
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer Exhibit 99.1 Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 - Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. ?I am delighted to welcome Cintia to our leadership |
|
| November 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 11, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or ot |
|
| November 12, 2021 |
Exhibit 99.1 Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS ? - SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - ? - The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) a |
|
| November 4, 2021 |
Exhibit 99.1 ? Adaptimmune Reports Third Quarter Financial Results and Business Update ? - Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - ? - SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tumors: overall response rate of 36% and 86% disease control |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 4, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or oth |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 4, 2021 |
Exhibit 10.1 CONFIDENTIAL ? certain identified information CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT because it is both not material and is the type that the registrant treats as private or confidential. STRATEGIC COLLABORATION AND LICENSE AGREEMENT AMONG ADAPTIMMUNE LIMITED, on the one hand, AND GENENTECH, INC. AND F. Hoffmann-La Roche Ltd, on the other hand |
|
| September 13, 2021 |
Exhibit 99.1 Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial ? - Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - ? - Majority of patients ex |
|
| September 13, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 13, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or o |
|
| September 7, 2021 |
Exhibit 99.1 Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies ? - Combining both companies? cell therapy leadership and expertise, the collaboration covers the research and development of ?off-the-shelf? cell therapies for up to five shared cancer targets and the development of a novel allogeneic pe |
|
| September 7, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 3, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or ot |
|
| August 20, 2021 |
Exhibit 10.1 ? ? ? ? ? ? ? ? ? DATED 20th August 2021 ? ? ? ? ? ? ? (1) MEPC MILTON PARK NO.1 LIMITED AND MEPC MILTON PARK NO.2 LIMITED ? ? ? and ? ? ? (2) ADAPTIMMUNE LIMITED ? ? ? ? deed of variation ? ? relating to a lease of ? ? 39 innovation drive Milton Park ? ? ? ? ? ? ? ? ? ? ? ? Knights plc Midland House West Way Botley Oxford OX2 0PH ? ? ? PARTICULARS DATE : 20th August 2021 ? LANDLORD ? |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporat |
|
| August 20, 2021 |
Exhibit 10.2 ? ? ? ? Dated 20TH aUGUST 2021 ? ? ? (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited ? ? and ? ? (2) ADAPTIMMUNE LIMITED ? ? and ? ? (3) ADAPTIMMUNE therapeutics plc ? ? ? ? ? ? rent security deposit deed ? relating to ? 39 Innovation Drive and 60 Jubilee Avenue Milton Park ? ? ? ? ? ? Knights plc Midland House West Way Botley Oxford OX2 0PH ? Rent Security Depos |
|
| August 13, 2021 |
? ? ? ? Exhibit 10.2 ? ? ? ? DATED 13th August 2021 ? ? ? ? ? ? ? (1) MEPC MILTON PARK NO.1 LIMITED AND MEPC MILTON PARK NO.2 LIMITED ? ? and ? ? (2) ADAPTIMMUNE LIMITED ? ? and ? ? (3) ADAPTIMMUNE THERAPEUTICS PLC ? ? ? deed of variation ? ? relating to a lease of ? ? 60 Jubilee Avenue Milton Park ? ? ? ? ? ? ? Knights plc Midland House West Way Botley Oxford OX2 0PH ? ? ? PARTICULARS DATE : 13th |
|
| August 13, 2021 |
EX-10.1 2 adap-20210813xex10d1.htm EX-10.1 Exhibit 10.1 (1)Park No. 2 Limited Dated 13th August 2021 (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited and (2) adaptimmune limited and (3) adaptimmune THERAPEUTICS PLC agreement relating to 39 Innovation Drive and 60 Jubilee Avenue Milton Park Knights plc Midland House West Way Botley Oxford OX2 0PH THIS AGREEMENT is made the 13th |
|
| August 13, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 13, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or othe |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporati |
|
| August 9, 2021 |
Exhibit 99.1 ? Adaptimmune Reports Second Quarter Financial Results and Business Update ? - SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - ? - SURPASS trial data from 23 evaluable patients to be presented at ESMO - ? - ADP-A2AFP Phase 1 trial data from 11 evaluable patients in Group 3/Expansion to |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 19, 2021 ? ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? ? ? England and Wales ? 1-37368 ? Not Applicable (State or other j |
|
| May 19, 2021 |
Exhibit 99.1 Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune?s Phase 2 SPEARHEAD-1 Trial ? - Data will support BLA filing for afamitresgene autoleucel next year - ? - Responses observed across a broad range of antigen expression - ? - Initial safety and durability are encouraging - ? PHILADELPHIA, PA., and OXFORDSHIRE, U.K., May 19, |
|
| May 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 1-37368 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 6, 2021 |
Exhibit 99.1 ? Adaptimmune Reports First Quarter Financial Results and Business Update ? - Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - ? - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - ? - Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1 - ? - Astellas nominates second target as part of allogeneic |
|
| April 8, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 25, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
